Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone
At a press conference during the ASCO 2012 Annual Meeting in Chicage, June 1st - June 4th, Dr Ellen Lavoie Smith presented findings from a phase III study where it was discovered that duloxetine is effective in treating painful chemotherapy-induced peripheral neuropathy.
This finding will likely change oncology practice and offers an important new quality of life solution for patients.
Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone
Breast cancer survivorship
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Latest in EGFR mutated NSCLC
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights
Real-world behavioural restrictional practices of cancer patients